Changes After Suprachoroidal Injection.

Cataract Clinical Trial

Official title:

Changes Noted After Suprachoroidal Triamcinolone Acetonide Injection.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05288192
• Other study ID #: Rc-3-22
• Status: Recruiting
• Phase: N/A
• Start date: February 15, 2022
• Est. completion date: September 1, 2022

Study information

• Verified date: March 2022
• Source: Benha University
• Contact: Ahmed Abdelshafy
• Phone: 01222328766
• Email: ahmad4lg[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Changes after suprachoroidal injection are analyzed for statistical analysis.

Description:

Changes after suprachoroidal injection of triamcinolone acetonide are noted in various retinal diseases treated by this technique to address its effects over six months of follow-up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 1, 2022
• Est. primary completion date: August 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients prepared to suprachoroidal injection for various retinal diseases will be enrolled in the study.

• Bilateral retinal diseases that required interventions as diabetic macular edema, exudative retinal detachment, and serous chorioretinopathies.

Exclusion Criteria:

• Other retinal diseases that are not expected to improve after steroid injections as central retinal artery occlusion and age-related macular degenerations.

• Choroidal neovascularization that require anti-vascular endothelial growth factors.

• Patients refused to have steroid injections even after discussing the nature of their disease with them and the procedure to be done.

Related Conditions & MeSH terms

• Cataract
• Intraocular Pressure
• Macular Edema
• Retina; Change

Intervention

Drug:
• Suprachoroidal triamcinolone acetonide (SCTA) injection
Suprachoroidal injection of 4mg/0.1ml of triamcinolone acetonide.

Locations

Country	Name	City	State
Egypt	Benha University	Banha	QA

Sponsors (1)

Lead Sponsor	Collaborator
Benha University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in visual acuity	Changes in best corrected visual acuity after injection	Monthly after injection till six months of follow up
Primary	Changes in central foveal thickness	Changes in central macular thickness after injection	Monthly after injection till six months of follow up
Secondary	Changes in intraocular pressure	Changes in intraocular pressure after injection	Monthly after injection till six months of follow up
Secondary	Changes in lens	Cataract progression after injection	Monthly after injection till six months of follow up